At present, the amount of cancer cells in the biopsy should at least be sufficient for an analysis of the KRAS mutational status, since treatment with an epithelial growth factor receptor (EGFR) inhibitor could be an option in the future (7). This evidence concerns the gene EGFR and cancer.